Literature DB >> 19833403

Improvements in risk factor control among persons with diabetes in the United States: evidence and implications for remaining life expectancy.

Thomas J Hoerger1, Ping Zhang, Joel E Segel, Edward W Gregg, K M Venkat Narayan, Katherine A Hicks.   

Abstract

AIMS: To examine whether A1c, blood pressure, and cholesterol values changed for U.S. adults with diagnosed diabetes between 1988-1994 and 2005-2006. We then project the impact of these changes on life expectancy and diabetes-related complications.
METHODS: We estimated changes in hemoglobin A1c, blood pressure, and total cholesterol between 1988-1994 and 2005-2006 using regression analysis and data from the National Health and Nutrition Examination Survey. We projected the potential effects on life expectancy and complications using the CDC-RTI Diabetes Cost-Effectiveness Model.
RESULTS: A1c fell by 0.68 percentage points (P=0.001) among U.S. adults with diagnosed diabetes. Among those with diabetes and hypertension, systolic and diastolic blood pressure fell by 5.66 and 8.15mmHg, respectively (P=0.005 and P=0.001). Among those with diabetes and high cholesterol, total cholesterol fell by 36.41mg/dL (P=0.001). These improvements were projected to increase life expectancy for persons with newly diagnosed diabetes by 1.0 year.
CONCLUSIONS: Risk factor control has improved in the United States. Persons newly diagnosed with type 2 diabetes in 2005 have a better prognosis than persons diagnosed with diabetes 11 years earlier.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19833403     DOI: 10.1016/j.diabres.2009.09.017

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  15 in total

Review 1.  [Diabetic maculopathy and retinopathy. Functional and sociomedical significance].

Authors:  J G Garweg; A Wenzel
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

Review 2.  Multifactorial intervention to reduce cardiovascular events in type 2 diabetes.

Authors:  Swapnil N Rajpathak; Vikas Aggarwal; Frank B Hu
Journal:  Curr Diab Rep       Date:  2010-02       Impact factor: 4.810

Review 3.  Type 2 diabetes mellitus--current therapies and the emergence of surgical options.

Authors:  Harold E Lebovitz
Journal:  Nat Rev Endocrinol       Date:  2011-02-08       Impact factor: 43.330

Review 4.  Duodenal-jejunal bypass liner to treat type 2 diabetes mellitus in morbidly obese patients.

Authors:  Rodrigo Muñoz; Alex Escalona
Journal:  Curr Cardiol Rep       Date:  2014-03       Impact factor: 2.931

5.  Personalized medicine in Type 2 diabetes: what does the future hold?

Authors:  Richard W Grant; Deborah J Wexler
Journal:  Diabetes Manag (Lond)       Date:  2012-05

6.  Continuing disparities in cardiovascular risk factors and complications between aboriginal and Anglo-Celt Australians with type 2 diabetes: the Fremantle Diabetes Study.

Authors:  Timothy M E Davis; Kerry Hunt; Daniel McAullay; Stephen A P Chubb; Brett A Sillars; David G Bruce; Wendy A Davis
Journal:  Diabetes Care       Date:  2012-07-18       Impact factor: 19.112

7.  Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999-2008.

Authors:  Earl S Ford
Journal:  Diabetes Care       Date:  2011-04-19       Impact factor: 19.112

8.  Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from Translating Research Into Action for Diabetes (TRIAD).

Authors:  Ping Zhang; Morton B Brown; Dori Bilik; Ronald T Ackermann; Rui Li; William H Herman
Journal:  Diabetes Care       Date:  2012-07-26       Impact factor: 19.112

9.  Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008.

Authors:  Earl S Ford; Chaoyang Li; Allan Sniderman
Journal:  Cardiovasc Diabetol       Date:  2013-01-30       Impact factor: 9.951

10.  Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO).

Authors:  Hui Shao; Vivian Fonseca; Charles Stoecker; Shuqian Liu; Lizheng Shi
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.